BRAF validation in melanoma

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 1, 2010, Pages 31-34

  Flaherty, Keith ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTINEOPLASTIC AGENT; B RAF KINASE; CHIR 265; DACARBAZINE; GSK 2118436; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PLX 4032; RAF PROTEIN; SORAFENIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; XL 281; BRAF PROTEIN, HUMAN;

ARTHRALGIA; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; GENE MUTATION; HUMAN; KERATOACANTHOMA; MELANOMA; METASTASIS; NOTE; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; SKIN CARCINOGENESIS; TREATMENT OUTCOME; VIRUS ONCOGENE; ARTICLE; DRUG ANTAGONISM; GENETICS; MUTATION;

HUMANS; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 76149111971     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
2. Smalley KS. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol. 2010;130:28-37.
3. Chapman P, Puzanov I, Sosman J, et al. Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. European Journal of Cancer Supplements. 2009;7:5.
4. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27:Abstract 9000.